Trump administration advances plan for peptide drugs favored by RFK Jr.

The Trump administration is moving forward with a regulatory plan that would broaden the use of compounded peptide drugs. The proposal would allow interim access to certain peptide therapies and could enable label expansion for products such as Enspryng. Coverage of the development appears across a range of outlets. Reuters and the Associated Press both note the administration’s advance of the peptide plan, while Politico highlights that the proposal is slated for White House review.

Ars Technica reports that RFK Jr. has called for the FDA to look the other way on unproven peptides, linking his advocacy to the policy shift. Industry‑focused sites including Seeking Alpha and Endpoints News focus on market implications, noting a rise in Hims & Hers Health’s stock as HHS moves ahead and describing the FDA’s consideration of interim access and label expansion. Market participants, exemplified by the stock movement of Hims & Hers Health, are reacting to the prospect of a broader peptide market. The next steps involve formal review of the peptide plan by the White House, as indicated by Politico.

Investors and observers are expected to monitor further statements from HHS and the administration, as well as any additional commentary from RFK Jr. that could influence the trajectory of the policy. Future coverage will clarify whether the proposed changes translate into concrete regulatory actions.